Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
Since I last wrote about MOC in 2010, the most relevant news has not been within the program itself, but in the increasingly rancorous reaction against its requirements from physicians of all specialties. Regardless, it doesn’t look like ABPN is going to be ditching MOC any time soon, so this article pretty much lays out what you have to do, without (much) editorializing.
Viibryd has gone generic, but is it worth prescribing? We review all there is to know about vilazodone in this update from our #1 most read article of 2023.